Dear Editor,We read with great interest the article by Wu et al[1]which comprehensively assessed the outcomes of various interventions in 38 eyes of 35 patients with malignant glaucoma（MG）secondary to antiglaucoma s...Dear Editor,We read with great interest the article by Wu et al[1]which comprehensively assessed the outcomes of various interventions in 38 eyes of 35 patients with malignant glaucoma（MG）secondary to antiglaucoma surgery whowere followed up for an average of 27.1mo.展开更多
目的探讨维生素 A 棕榈酸酯眼用凝胶预防临床常用抗青光眼药物眼表损伤的作用。方法正常新西兰大白兔60只采用随机对照方式分为5组,每组12只(12眼)。A 组单纯使用维生素 A 棕榈酸酯眼用凝胶,B 组单纯使用0.5%噻吗洛尔滴眼液,C 组单纯使...目的探讨维生素 A 棕榈酸酯眼用凝胶预防临床常用抗青光眼药物眼表损伤的作用。方法正常新西兰大白兔60只采用随机对照方式分为5组,每组12只(12眼)。A 组单纯使用维生素 A 棕榈酸酯眼用凝胶,B 组单纯使用0.5%噻吗洛尔滴眼液,C 组单纯使用0.2%溴莫尼定滴眼液,D 组联合使用维生素 A 棕榈酸酯跟用凝胶及0.5%噻吗洛尔滴眼液,E 组则联合使用维生素 A 棕榈酸酯眼用凝胶及0.2%溴莫尼定滴眼液。用药前及用药1个月后分别进行泪膜破裂时间(tear break-up time,BUT)、基础泪液分泌试验(Schirmertest)及印迹细胞学检查,并通过扫描电镜观察各组角膜上皮形态。结果用药后 B 组及 C 组 BUT 为(11.6±1.9)s 和(10.9±3.1)s,较用药前的(18.6±3.9)s 和(16.5±4.3)s 缩短,并且结膜杯状细胞密度较用药前下降,二者差异有统计学意义(P<0.05)。A,D 及 E 组的BUT及结膜杯状细胞密度用药前后无明显变化。各组用药前后基础泪液分泌的差异均无统计学意义。B 组和 C 组用药后 Nelson 分级标准评为1级;A,D 及 E 组用药后仍为0级。扫描电镜结果表明 B 组及 C 组表现为表面粗糙,细胞失去平整性,卷边、脱落明显增多,细胞间出现裂隙,同时微绒毛密度明显减少。结论长期使用抗青光眼药物可导致兔角膜及结膜结构变化。维生素A棕榈酸酯通过维持泪膜的稳定性及结膜杯状细胞密度,能够有效地减轻临床常用抗青光眼药造成的眼表损伤。(中国眼耳鼻喉科杂志,2007,7:356-358)展开更多
目的观察维生素A棕榈酸酯眼用凝胶对抗青光眼药物眼表损伤的防治作用。方法选取需要长期应用抗青光眼药物治疗的患者64例90眼,根据用药种类分为两组:噻吗心安组和曲伏前列腺素组。又将两组采用随机对照方式各分为两个亚组:噻吗心安组,...目的观察维生素A棕榈酸酯眼用凝胶对抗青光眼药物眼表损伤的防治作用。方法选取需要长期应用抗青光眼药物治疗的患者64例90眼,根据用药种类分为两组:噻吗心安组和曲伏前列腺素组。又将两组采用随机对照方式各分为两个亚组:噻吗心安组,噻吗心安+维生素A组,曲伏前列素组,曲伏前列素+维生素A组。用药前及用药3个月后分别进行眼压(Intraocular pressure,IOP)、泪膜破裂时间(Break-up time,BUT)、泪液分泌试验(Schirmer test I,STI)和干眼仪检查,了解用药前后的变化。结果用药后各组的10P均明显下降,差异均有统计学意义。而用药后噻吗心安组和噻吗心安+维生素A组,曲伏前列素组和曲伏前列素+维生素A组IOP差异无统计学意义。用药3个月后噻吗心安组和曲伏前列素组BUT为(6.59±2.51)s和(5.54±1.93)s,较用药前的(7.86±2.61)s和(6.96±1.71)s缩短,差异有统计学意义;STI为(7.23±2.78)mm和(5.96±1.94)mm,较用药前的(8.91±3.41)mm和(7.83±2.84)mm减少,差异有统计学意义;干眼仪正常百分率为22.73%和29.17%,较用药前的54.54%和62.50%降低,差异有统计学意义。用药3个月后噻吗心安+维生素A组和曲伏前列素+维生素A组BUT为(7.75±2.34)s和(7.21±2.21)s,与用药前的(7.95±2.74)s和(7.17±2.20)s相比,差异无统计学意义;STI为(8.65±2.03)mm和(8.63±2.43)mm,与用药前的(8.45±3.14)mm和(8.45±3.14)mm相比,差异无统计学意义;干眼仪正常百分率为55.00%和70.83%,与用药前的65.00%和66.67%相比,差异无统计学意义。结论长期使用抗青光眼药物会造成眼表结构的损害,而维生素A棕榈酸眼用凝胶可以预防抗青光眼药物所造成的眼表损伤且不影响降眼压药物的吸收。展开更多
目的通过对长期滴用抗青光眼药物患者的症状、眼部检查、实验室指标的分析,了解抗青光眼药物对眼表结构的影响,并对引起眼表结构改变的机理进行分析和探讨。方法29例(50只眼)长期局部滴用抗青光眼药物的患者均给予详细询问病史、眼部常...目的通过对长期滴用抗青光眼药物患者的症状、眼部检查、实验室指标的分析,了解抗青光眼药物对眼表结构的影响,并对引起眼表结构改变的机理进行分析和探讨。方法29例(50只眼)长期局部滴用抗青光眼药物的患者均给予详细询问病史、眼部常规检查和干眼实验检查:Sch irm er 1、BUT、眼表活体染色、印痕细胞(C IC)检查。结果表麻下的Sch irm er 1、BUT的值均低于正常,角膜荧光素染色评分和虎红染色评分、印痕细胞评分均高。结论长期局部滴用抗青光眼药物可引影响眼表正常结构。展开更多
AIM: To evaluate the short-term effect of the fixed combination of brinzolamide-timolol on the ocular surface in glaucoma patients. METHODS: This is a prospective study of 23 eyes of 23 patients with newly diagnosed g...AIM: To evaluate the short-term effect of the fixed combination of brinzolamide-timolol on the ocular surface in glaucoma patients. METHODS: This is a prospective study of 23 eyes of 23 patients with newly diagnosed glaucoma. Schirmer Ⅰ test, tear break-up time (BUT) measurement, conjunctival impression cytology and central corneal thickness (CCT) measurements were performed in one of the eyes of each patients before and 4 weeks after brinzolamide-timolol fixed combination therapy. All patients were asked to answer the OSDI questionnaire form about the ocular surface symptoms at baseline and at 1 week and 4 weeks follow-up visits. RESULTS: After brinzolamide-timolol fixed combination theraphy, Schirmer Ⅰ, BUT and CCT values decreased but the only statistically significant decrease was seen in BUT test (P =0.03). OSDI scores increased during the follow-up but this increase was not statistically significant (P =0.22, P = 0.42 respectively). Impression cytology findings ranged from 0.78±0.42 to 0.95±0.36 according to the Nelson classification. There was no statistically significant difference between baseline and 4 weeks follow up in impression cytology grades (P =0.15). CONCLUSION: The results of our study indicate that short-term use of brinzolamide-timolol fixed combination theraphy does not have a profound effect on ocular surface except BUT values.展开更多
文摘Dear Editor,We read with great interest the article by Wu et al[1]which comprehensively assessed the outcomes of various interventions in 38 eyes of 35 patients with malignant glaucoma（MG）secondary to antiglaucoma surgery whowere followed up for an average of 27.1mo.
文摘目的探讨维生素 A 棕榈酸酯眼用凝胶预防临床常用抗青光眼药物眼表损伤的作用。方法正常新西兰大白兔60只采用随机对照方式分为5组,每组12只(12眼)。A 组单纯使用维生素 A 棕榈酸酯眼用凝胶,B 组单纯使用0.5%噻吗洛尔滴眼液,C 组单纯使用0.2%溴莫尼定滴眼液,D 组联合使用维生素 A 棕榈酸酯跟用凝胶及0.5%噻吗洛尔滴眼液,E 组则联合使用维生素 A 棕榈酸酯眼用凝胶及0.2%溴莫尼定滴眼液。用药前及用药1个月后分别进行泪膜破裂时间(tear break-up time,BUT)、基础泪液分泌试验(Schirmertest)及印迹细胞学检查,并通过扫描电镜观察各组角膜上皮形态。结果用药后 B 组及 C 组 BUT 为(11.6±1.9)s 和(10.9±3.1)s,较用药前的(18.6±3.9)s 和(16.5±4.3)s 缩短,并且结膜杯状细胞密度较用药前下降,二者差异有统计学意义(P<0.05)。A,D 及 E 组的BUT及结膜杯状细胞密度用药前后无明显变化。各组用药前后基础泪液分泌的差异均无统计学意义。B 组和 C 组用药后 Nelson 分级标准评为1级;A,D 及 E 组用药后仍为0级。扫描电镜结果表明 B 组及 C 组表现为表面粗糙,细胞失去平整性,卷边、脱落明显增多,细胞间出现裂隙,同时微绒毛密度明显减少。结论长期使用抗青光眼药物可导致兔角膜及结膜结构变化。维生素A棕榈酸酯通过维持泪膜的稳定性及结膜杯状细胞密度,能够有效地减轻临床常用抗青光眼药造成的眼表损伤。(中国眼耳鼻喉科杂志,2007,7:356-358)
文摘目的观察维生素A棕榈酸酯眼用凝胶对抗青光眼药物眼表损伤的防治作用。方法选取需要长期应用抗青光眼药物治疗的患者64例90眼,根据用药种类分为两组:噻吗心安组和曲伏前列腺素组。又将两组采用随机对照方式各分为两个亚组:噻吗心安组,噻吗心安+维生素A组,曲伏前列素组,曲伏前列素+维生素A组。用药前及用药3个月后分别进行眼压(Intraocular pressure,IOP)、泪膜破裂时间(Break-up time,BUT)、泪液分泌试验(Schirmer test I,STI)和干眼仪检查,了解用药前后的变化。结果用药后各组的10P均明显下降,差异均有统计学意义。而用药后噻吗心安组和噻吗心安+维生素A组,曲伏前列素组和曲伏前列素+维生素A组IOP差异无统计学意义。用药3个月后噻吗心安组和曲伏前列素组BUT为(6.59±2.51)s和(5.54±1.93)s,较用药前的(7.86±2.61)s和(6.96±1.71)s缩短,差异有统计学意义;STI为(7.23±2.78)mm和(5.96±1.94)mm,较用药前的(8.91±3.41)mm和(7.83±2.84)mm减少,差异有统计学意义;干眼仪正常百分率为22.73%和29.17%,较用药前的54.54%和62.50%降低,差异有统计学意义。用药3个月后噻吗心安+维生素A组和曲伏前列素+维生素A组BUT为(7.75±2.34)s和(7.21±2.21)s,与用药前的(7.95±2.74)s和(7.17±2.20)s相比,差异无统计学意义;STI为(8.65±2.03)mm和(8.63±2.43)mm,与用药前的(8.45±3.14)mm和(8.45±3.14)mm相比,差异无统计学意义;干眼仪正常百分率为55.00%和70.83%,与用药前的65.00%和66.67%相比,差异无统计学意义。结论长期使用抗青光眼药物会造成眼表结构的损害,而维生素A棕榈酸眼用凝胶可以预防抗青光眼药物所造成的眼表损伤且不影响降眼压药物的吸收。
文摘目的通过对长期滴用抗青光眼药物患者的症状、眼部检查、实验室指标的分析,了解抗青光眼药物对眼表结构的影响,并对引起眼表结构改变的机理进行分析和探讨。方法29例(50只眼)长期局部滴用抗青光眼药物的患者均给予详细询问病史、眼部常规检查和干眼实验检查:Sch irm er 1、BUT、眼表活体染色、印痕细胞(C IC)检查。结果表麻下的Sch irm er 1、BUT的值均低于正常,角膜荧光素染色评分和虎红染色评分、印痕细胞评分均高。结论长期局部滴用抗青光眼药物可引影响眼表正常结构。
文摘AIM: To evaluate the short-term effect of the fixed combination of brinzolamide-timolol on the ocular surface in glaucoma patients. METHODS: This is a prospective study of 23 eyes of 23 patients with newly diagnosed glaucoma. Schirmer Ⅰ test, tear break-up time (BUT) measurement, conjunctival impression cytology and central corneal thickness (CCT) measurements were performed in one of the eyes of each patients before and 4 weeks after brinzolamide-timolol fixed combination therapy. All patients were asked to answer the OSDI questionnaire form about the ocular surface symptoms at baseline and at 1 week and 4 weeks follow-up visits. RESULTS: After brinzolamide-timolol fixed combination theraphy, Schirmer Ⅰ, BUT and CCT values decreased but the only statistically significant decrease was seen in BUT test (P =0.03). OSDI scores increased during the follow-up but this increase was not statistically significant (P =0.22, P = 0.42 respectively). Impression cytology findings ranged from 0.78±0.42 to 0.95±0.36 according to the Nelson classification. There was no statistically significant difference between baseline and 4 weeks follow up in impression cytology grades (P =0.15). CONCLUSION: The results of our study indicate that short-term use of brinzolamide-timolol fixed combination theraphy does not have a profound effect on ocular surface except BUT values.
